1 %. Baseline pressures and average pressures on the previous treatment were established. Substitution with Ganda 3 05 or 5*05 was started, and the patients attended 2 weeks, 1 month, 3 months, and 6 months from the start of the trial. Applanation tonometry was carried out at the same time of day. The pupil was measured, ptosis and superficial punctate corneal staining were looked for and evaluated, and the patients were questioned for symptoms of side effects and acceptability. All the eyes that had previously been treated with pilocarpine 1% or 2% presented significantly lower intraocular pressures on Ganda 3 05. The patients on pilocarpine 4 % and adrenaline I % also had lower intraocular pressures on Ganda 5 05, but the significance was less, and the patients on separate guanethidine and adrenaline had a small but not statistically significant drop in pressure. Ptosis and discomfort were evaluated on a subjective scale. Patient acceptability was good. The trial was interrupted in 5 cases for various reasons. Tachyphylaxis and tolerance to the mixtures were not observed in this series.
Interest in guanethidine and other beta-blocking agents for the possible lowering of intraocular pressure goes back to the early 1960s. Guanethidine eye drops were being successfully used to diminish the lid retraction produced by sympathetic overactivity associated with thyrotoxicosis. However, attempts by one of us (J.R.) to control the intraocular pressure in several cases with both thyrotoxicosis and open-angle glaucoma with topical guanethidine were not successful. Other workers (Stepanik, 1961; Castren and Pohjola, 1962; Anselmi et al., 1968) reported a lowering of the intraocular pressure using guanethidine alone. The discrepancy between these results will be discussed later in this paper. The combination of adrenaline with guanethidine provided a breakthrough (Paterson and Paterson, 1972) , and several studies attest to the efficacy of this combined therapy (Roth 1973; Gloster, 1974; Crombie, 1974; Paterson et al., 1975; Etienne, 1975; Nagasubramanian et al., 1976) .
These trials were practically all concerned with new and untreated cases of glaucoma or cases in which all previous treatment had been discontinued. More recently a trial was carried out on severe cases of open-angle glaucoma most of which were already on maximal medical therapy. The addition of guanethidine and adrenaline eye drops to the previous treatment led to a satisfactory response in most cases (Romano, 1977) . The guanethidine and adrenaline eye drops were used 10 minutes apart to enhance absorption (Phillips, 1971) , and this was repeated twice a day. It was felt that a mixture of the 2 drugs would be more convenient for the patient. However, it was not known at the time whether it would be possible to mix the 2 drugs in a stable solution and whether the efficacy and absorption of the mixture would be adequate. The availability of such a mixture has made this study possible.
Material and methods
The study covers 90 eyes in 53 patients drawn from the Glaucoma Clinics of both branches of Moor-52 to the 1.0 setting and directed at an angle of 30°f rom the temporal side. At each visit the following were searched for and estimated: Ptosis (measured in millimetres); hyperaemia of the bulbar conjunctiva and of the eyelids, and lid-sensitivity reaction; punctate epitheliopathy, by fluorescein staining of the cornea.
The patients were closely questioned for symptoms such as discomfort, browache, burning, and blurring of vision. The fields of vision, charted before the trial, were compared with those at the end of the trial.
At the end of the trial, the average intraocular pressures, average pupil diameter, and degree of ptosis were noted. The symptoms were assessed on a subjective scale: Discomfort was described as nil, minimal (m), moderate (M), or severe (S). Ptosis was described as nil, minimal (1 to 2 mm), moderate (2 to 3 mm), or severe (more than 3 mm). Punctate epitheliopathy was described as present (+1) or absent (-).
Results
See Tables 1 and 2 for analysis of results.
In 9 out of 9 cases previously on pilocarpine 1 % 2 to 4 times a day compared with Ganda 3 05 the average pressure was lower on the guanethidineadrenaline mixture. The average intraocular pressure on pilocarpine 1 % was 24 mm (SD 2-1), and on Ganda 3 05 18-20 mm (SD 2 7) (t= 10-9, P<0 001).
All 10 cases previously on pilocarpine 2%
3 to 4 times a day compared with Ganda 3 05 had (Romano, 1977) two possibilities regarding the mode of action of guanethidine were invisaged: (1) The hypersensitisation effect is created anew, or at least 'topped up' with each instillation of guanethidine; (2) it gradually builds up over several days with repeated instillations.
If the first view is the correct one, separate administration of guanethidine followed by adrenaline after a suitable interval would be the logical way to use the drugs. However, in some cases the effect of these drugs has been observed (Paterson and Paterson, 1972) to be delayed for some weeks, which supports the second view. Furthermore, the use of a mixture of the 2 substances has proved to be at least as effective-and in the present series it has been marginally more successful-than that of separate administration. If this is so, the added convenience to the patient of a single instillation must make the mixture the treatment of choice.
In this context the difference in the success-rate reported by various workers with topical guanethidine alone is interesting.
SIDE EFFECTS
Ganda has been well tolerated by the patients in this trial, the intolerance rate being around 5-5%. This improved tolerance can be attributed to the use of 0-5% adrenaline instead of the more traditional I % solution. Discomfort, when present, was usually an initial sensation of grittiness and browache, passing off with continued use of the drops. It was often transient, lasting a minute or two only. As regards ptosis, in 1 case vision was impaired by a 'severe' ptosis of 3 to 4 mm. Although minimal ptosis was a frequent finding, the patients were usually unaware of it. Moderate or severe ptosis could cause some cosmetic disability. Hyperaemia was severe in a dozen or so cases; it was certainly not so marked as has been observed with 1% adrenaline. Punctate epitheliopathy, a rare finding, was associated, when present, with discomfort in about half the cases. Five cases were rejected from the trial for intolerance to the drops, probably to adrenaline; 1 case for poor control of pressures with small visual fields; and 2 cases for mistakenly using pilocarpine along with Ganda for one or more visits.
Where little or no hypertensive effect is achieved, it may be speculated that local or circulating catecholamines are not sufficient in some individuals, in spite of the hypersensitisation of the adrenergic receptors, to produce a significant lowering of the intraocular pressure, the reverse being true in other individuals.
VISUAL FIELDS
There was no evidence of field loss or of any increase in pre-existing field loss in any patient during the 6-month period of the trial. As mentioned above, 1 case with previously very constricted fields was withdrawn from the trial as his intraocular pressures were considered to be insufficiently controlled.
TACHYPHYL AXIS AND ACCOMMODATION TO GANDA Tachyphylaxis, defined as the loss of effectivity of a a drug occurring early (i.e., in the first few days of treatment), was not specifically studied. It is, however, unlikely to occur, as guanethidine and adrenaline mixtures appear gradually to build up to their maximum effectivity, often over the first few Evaluation ofguanethidine and adrenaline mixtures weeks. Accommodation, defined as a gradual loss of effectivity over a longer period, did not seem to occur in this series (Tables 1 and 2 ).
Conclusion
In our series the ocular hypotensive action of Ganda 3 05 was significantly greater than that of pilocarpine 1 % 2 to 3 times a day, pilocarpine 2% 3 to 4 times a day, and of pilocarpine 2 to 4% 4 times a day, with adrenaline 1 % twice daily. Most 
